BACKGROUND: A reduced willingness to perform effort based on the magnitude and probability of potential rewards has been associated with diminished dopamine function and may be relevant to attention-deficit/hyperactivity disorder (ADHD). Here, we investigated the influence of ADHD status and methylphenidate on effort-based decisions. We hypothesized that ADHD participants would make fewer high-effort selections than non-ADHD subjects, and that methylphenidate would increase the number of high-effort selections. Furthermore, we hypothesized there would be associations among ADHD severity and methylphenidate-related changes in effort-based and attentional performance across all participants. METHODS AND PARTICIPANTS: ADHD (n = 23) and non-ADHD (n = 23) adults completed the Effort Expenditure for Rewards Task in which participants select between low-effort and high-effort options to receive monetary rewards at varying levels of reward magnitude and probability. A test of attentional performance was also completed. RESULTS: Overall, participants made more high-effort selections as potential reward magnitude and probability increased. ADHD participants did not make fewer high-effort selections than non-ADHD participants, but ADHD participants showed greater methylphenidate-related increases in high-effort selections. ADHD participants had worse attentional performance than non-ADHD participants. ADHD severity was associated with methylphenidate-related changes in high-effort selections, but not changes in attentional performance. CONCLUSIONS: These results indicate that methylphenidate increases the willingness to perform effort in individuals with ADHD, possibly due to disorder-related motivational deficits. This provides support for theories of insufficient effort allocation among individuals with ADHD. TRIAL REGISTRATION: Clinicaltrials.gov Identifier, NCT02630017.
BACKGROUND: A reduced willingness to perform effort based on the magnitude and probability of potential rewards has been associated with diminished dopamine function and may be relevant to attention-deficit/hyperactivity disorder (ADHD). Here, we investigated the influence of ADHD status and methylphenidate on effort-based decisions. We hypothesized that ADHDparticipants would make fewer high-effort selections than non-ADHD subjects, and that methylphenidate would increase the number of high-effort selections. Furthermore, we hypothesized there would be associations among ADHD severity and methylphenidate-related changes in effort-based and attentional performance across all participants. METHODS AND PARTICIPANTS: ADHD (n = 23) and non-ADHD (n = 23) adults completed the Effort Expenditure for Rewards Task in which participants select between low-effort and high-effort options to receive monetary rewards at varying levels of reward magnitude and probability. A test of attentional performance was also completed. RESULTS: Overall, participants made more high-effort selections as potential reward magnitude and probability increased. ADHDparticipants did not make fewer high-effort selections than non-ADHDparticipants, but ADHDparticipants showed greater methylphenidate-related increases in high-effort selections. ADHDparticipants had worse attentional performance than non-ADHDparticipants. ADHD severity was associated with methylphenidate-related changes in high-effort selections, but not changes in attentional performance. CONCLUSIONS: These results indicate that methylphenidate increases the willingness to perform effort in individuals with ADHD, possibly due to disorder-related motivational deficits. This provides support for theories of insufficient effort allocation among individuals with ADHD. TRIAL REGISTRATION: Clinicaltrials.gov Identifier, NCT02630017.
Authors: L Felice Reddy; William P Horan; Deanna M Barch; Robert W Buchanan; Eduardo Dunayevich; James M Gold; Naomi Lyons; Stephen R Marder; Michael T Treadway; Jonathan K Wynn; Jared W Young; Michael F Green Journal: Schizophr Bull Date: 2015-07-03 Impact factor: 9.306
Authors: John J Chelonis; Teresa A Johnson; Sherry A Ferguson; Kimberly J Berry; Brian Kubacak; Mark C Edwards; Merle G Paule Journal: Exp Clin Psychopharmacol Date: 2011-04 Impact factor: 3.157
Authors: Merideth A Addicott; John M Pearson; Julia C Schechter; Jeffrey J Sapyta; Margaret D Weiss; Scott H Kollins Journal: Neuropsychopharmacology Date: 2020-10-11 Impact factor: 7.853
Authors: Heather E Webber; Paula Lopez-Gamundi; Sydney N Stamatovich; Harriet de Wit; Margaret C Wardle Journal: Neurosci Biobehav Rev Date: 2020-11-14 Impact factor: 8.989